Vaccines against viral hemorrhagic fevers: Non-human primate models

Human Vaccines

Volumn 7, Issue 6, 2011, Pages 667-673

  Carrion, Ricardo ^a,b   Patterson, Jean L ^a  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Ebola; Junin; Lassa; Macaque; Marburg; Marmoset; Monkey; Rift valley fever

Indexed keywords

CANDID 1 VACCINE; LIVE VACCINE; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ARENAVIRUS; ARGENTINE HEMORRHAGIC FEVER; BUNYAVIRUS; CLINICAL FEATURE; DISEASE MODEL; DRUG SCREENING; EBOLA VIRUS; FILOVIRUS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INFECTION PREVENTION; LASSA FEVER; MARBURG VIRUS; NONHUMAN; REVIEW; VACCINATION; VIRUS GENOME; VIRUS HEMORRHAGIC FEVER; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; DISEASE MODELS, ANIMAL; HEMORRHAGIC FEVERS, VIRAL; HUMANS; PRIMATES; VIRAL VACCINES;

EID: 79959370875     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.6.14981     Document Type: Review

References (73)

1. Bray M. Pathogenesis of viral hemorrhagic fever. Curr Opin Immunol 2005; 17:399-403; PMID: 15955687.
2. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhage fever: Evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196:400-3.
3. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009; 2:12-7; PMID: 19132113.
4. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7:393-400; PMID: 19369954.
5. Roberts R, Styrt B, McCune S. FDA perspective on antivirals against biothreats: communicate early and often. Antiviral Res 2008; 78:60-3; PMID: 18037169.
6. Knipe, David M, Peter M. Howley. Fields Virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins 2007; 5:2.
7. McCormick JB, Fisher-Hoch SP. Lassa fever. Curr Top Microbiol Immunol 2002; 262:75-109; PMID: 11987809.
8. McCormick JB, Walker DH, King IJ, Webb PA, Elliott LH, Whitfield SG, et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg 1986; 35:401-7. (Pubitemid 16055415)
9. McCormick JB. Lassa fever: epidemiology, therapy and vaccine development. Kansenshogaku Zasshi 1988; 62:353-66; PMID: 3953952.
10. McCormick JB. Epidemiology and control of Lassa fever. Curr Top Microbiol Immunol 1987; 134:69-78; PMID: 3581899.
11. McCormick JB. Clinical, epidemiologic and therapeutic aspects of Lassa fever. Med Microbiol Immunol 1986; 175:153-5; PMID: 3724661.
12. Walker DH, McCormick JB, Johnson KM, Webb PA, Komba-Kono G, Elliott LH, et al. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 1982; 107:349-56; PMID: 7081389.
13. Tandon BN, Acharya SK. Viral diseases involving the liver. Baillieres Clin Gastroenterol 1987; 1:211-30; PMID: 2822180.
14. Callis RT, Jahrling PB, DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am J Trop Med Hyg 1982; 31:1038-45; PMID: 7125056.
15. Stephen EL, Jahrling PB. Experimental Lassa fever virus infection successfully treated with ribavirin. Lancet 1979; 1:268-9; PMID: 84919.
16. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 1980; 141:580-9; PMID: 6768812.
17. Walker DH, Johnson KM, Lange JV, Gardner JJ, Kiley MP, McCormick JB. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J Infect Dis 1982; 146:360-8; PMID: 6286795.
18. Fisher-Hoch SP, Platt GS, Lloyd G, Simpson DI, Neild GH, Barrett AJ. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet 1983; 2:1055-8; PMID: 6138602.
19. Carrion R Jr, Brasky K, Mansfield K, Johnson C, Gonzales M, Ticer A, et al. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol 2007; 81:6482-90; PMID: 17409137.
20. Lukashevich IS, Carrion R Jr, Salvato MS, Mansfield K, Brasky K, Zapata J, et al. Safety, immunogenicity and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 2008; 26:5246-54; PMID: 18692539.
21. Winn WC Jr, Monath TP, Murphy FA, Whitfield SG. Lassa virus hepatitis. Observations on a fatal case from the 1972 Sierra Leone epidemic. Arch Pathol 1975; 99:599-604; PMID: 1227472.
22. Baize S, Pannetier D, Faure C, Marianneau P, Marendat I, Georges-Courbot MC, et al. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect 2006; 8:1194-202; PMID: 16621649.
23. Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 2004; 172:2861-9; PMID: 14978087.
24. Lukashevich IS, Maryankova R, Vladyko AS, Nashkevich N, Koleda S, Djavani M, et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNFalpha gene expression. J Med Virol 1999; 59:552-60; PMID: 10534741.
25. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170:2797-801; PMID: 12626527.
26. Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, Alexander J, et al. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol 84:9947-56; PMID: 20668086.
27. Rodas JD, Lukashevich IS, Zapata JC, Cairo C, Tikhonov I, Djavani M, et al. Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. J Med Virol 2004; 72:424-35; PMID: 14748066.
28. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005; 2:183; PMID: 15971954.
29. Walker DH, Wulff H, Murphy FA. Experimental Lassa virus infection in the squirrel monkey. Am J Pathol 1975; 80:261-78; PMID: 1163630.
30. Maiztegui JI, McKee KT Jr, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 1998; 177:277-83; PMID: 9466512.
31. McKee KT Jr, Mahlandt BG, Maiztegui JI, Eddy GA, Peters CJ. Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response. J Infect Dis 1985; 152:218-21; PMID: 2989384.
32. Kenyon RH, McKee KT Jr, Zack PM, Rippy MK, Vogel AP, York C, et al. Aerosol infection of rhesus macaques with Junin virus. Intervirology 1992; 33:23-31; PMID: 1371270.
33. Gonzalez PH, Laguens RP, Frigerio MJ, Calello MA, Weissenbacher MC. Junin virus infection of Callithrix jacchus: pathologic features. Am J Trop Med Hyg 1983; 32:417-23; PMID: 6301303.
34. Samoilovich SR, Rondinone SN, Laguens RP, Colillas O, Frigerio MJ, Weissenbacher MC. [Infection of New World primates with Junin virus. IV. Aotus trivirgatus]. Rev Argent Microbiol 1983; 15:219-22; PMID: 6101070.
35. Tesh RB, Jahrling PB, Salas R, Shope RE. Description of Guanarito virus (Arenaviridae: Arenavirus), the etiologic agent of Venezuelan hemorrhagic fever. Am J Trop Med Hyg 1994; 50:452-9; PMID: 8166352.
36. McLeod CG, Stookey JL, Eddy GA, Scott K. Pathology of chronic Bolivian hemorrhagic fever in the rhesus monkey. Am J Pathol 1976; 84:211-24; PMID: 181994.
37. Kastello MD, Eddy GA, Kuehne RW. A rhesus monkey model for the study of Bolivian hemorrhagic fever. J Infect Dis 1976; 133:57-62; PMID: 173762.
38. Eddy GA, Scott SK, Wagner FS, Brand OM. Pathogenesis of Machupo virus infection in primates. Bull World Health Organ 1975; 52:517-21; PMID: 182402.
39. McLeod CG Jr, Stookey JL, White JD, Eddy GA, Fry GA. Pathology of Bolivian Hemorrhagic fever in the African green monkey. Am J Trop Med Hyg 1978; 27:822-6; PMID: 99059.
40. Yanagihara R, Amyx HL, Lee PW, Asher DM, Gibbs CJ Jr, Gajdusek DC. Experimental hantavirus infection in nonhuman primates. Arch Virol 1988; 101:125-30; PMID: 3137914.
41. Groen J, Gerding M, Koeman JP, Roholl PJ, van Amerongen G, Jordans HG, et al. A macaque model for hantavirus infection. J Infect Dis 1995; 172:38-44; PMID: 7797944.
42. Mertens M, Essbauer SS, Rang A, Schroder J, Splettstoesser WD, Kretzschmar C, et al. Non-human primates in outdoor enclosures: Risk for infection with rodent-borne hantaviruses. Vet Microbiol 2010; [Epub ahead of print]; PMID: 20727685.
43. Morrill JC, Knauert FK, Ksiazek TG, Meegan JM, Peters CJ. Rift Valley fever infection of rhesus monkeys: implications for rapid diagnosis of human disease. Res Virol 1989; 140:139-46; PMID: 2756241.
44. Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol 2007; 8:1159-64; PMID: 17952040.
45. Groseth A, Feldmann H, Strong JE. The ecology of Ebola virus. Trends Microbiol 2007; 15:408-16; PMID: 17698361.
46. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487-98; PMID: 15288821.
47. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004; 78:4330-41; PMID: 15047846.
48. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1999; 179:248-58; PMID: 9988191.
49. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179:203-17; PMID: 9988186.
50. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7; PMID: 11996686.
51. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, Huggins JW, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996; 11:135-40; PMID: 8800795.
52. Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003; 3:677-85; PMID: 12974482.
53. Peterson AT, Carroll DS, Mills JN, Johnson KM. Potential mammalian filovirus reservoirs. Emerg Infect Dis 2004; 10:2073-81; PMID: 15663841.
54. Peterson AT, Bauer JT, Mills JN. Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis 2004; 10:40-7; PMID: 15078595.
55. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999; 179:199-202; PMID: 9988185.
56. Ryabchikova EI, Kolesnikova LV, Netesov SV. Animal pathology of filoviral infections. Curr Top Microbiol Immunol 1999; 235:145-73; PMID: 9893383.
57. Fisher-Hoch SP, Brammer TL, Trappier SG, Hutwagner LC, Farrar BB, Ruo SL, et al. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis 1992; 166:753-63; PMID: 1527410.
58. Fisher-Hoch SP, McCormick JB. Experimental filovirus infections. Curr Top Microbiol Immunol 1999; 235:117-43; PMID: 9893382.
59. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163:2371-82; PMID: 14633609.
60. Simpson DI. Marburg agent disease: in monkeys. Trans R Soc Trop Med Hyg 1969; 63:303-9; PMID: 4978540.
61. Oswald WB, Gesibert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007; 3:9.
62. Simpson DI, Zlotnik I, Rutter DA. Vervet monkey disease. Experiment infection of guinea pigs and monkeys with the causative agent. Br J Exp Pathol 1968; 49:458-64; PMID: 5727750.
63. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70; PMID: 14633608.
64. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82:5664-8; PMID: 18385248.
65. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618-29; PMID: 14639531.
66. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, Topper M, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120:140-55; PMID: 8712894.
67. Larsen T, Stevens EL, Davis KJ, Geisbert JB, Daddario-DiCaprio KM, Jahrling PB, et al. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis 2007; 196:323-8; PMID: 17940967.
68. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37; PMID: 9813200.
69. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, Young HA, Formenty P, Fritz EA, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007; 196:372-81; PMID: 17940973.
70. Johnson ED, Johnson BK, Silverstein D, Tukei P, Geisbert TW, Sanchez AN, et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch Virol Suppl 1996; 11:101-14; PMID: 8800792.
71. Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010; 16:1119-22; PMID: 20587184.
72. Zlotnik I, Simpson DI, Howard DM. Structure of the vervet-monkey-disease agent. Lancet 1968; 2:26-8; PMID: 4172689.
73. Mansfield K. Marmoset models commonly used in biomedical research. Comp Med 2003; 53:383-92; PMID: 14524414.